Dexcom started in 1967 with researches on implanted glucose sensors conducted at the University of Wisconsin. The research aimed at the creation of an implantable sensor that would not be rejected by the human body and that would perform for extended periods of time. This humble beginning grew to what Dexcom is now: owner of more than 40 patents and has developed the proprietary Dexcom’s Sensor technology.
Since its founding, Dexcom has developed multiple generations of its sensor technology. The Food and Drug Administration approved Dexcom’s STS Continuous Glucose Monitoring System in 2006. This technology is capable of providing 288 glucose measurements every 24 hours for three days. A second generation of these products called Seven Continuous Glucose Monitoring System was also approved in May 2007. The second generation featured improved accuracy and with extended usage from three days to seven days.
Dexcom entered into two separate consumer development agreements with Animas Corporation and Insulet Corporation in 2008. It also engaged Edwards Lifesciences in a development agreement for continuous glucose monitoring systems for ICU patients. A third generation continuous glucose monitoring system called SEVEN PLUS Continuous Glucose Monitor was launched in February 2009 after the FDA approved its registration. In November 2009, this product received a CE mark.
The SEVEN PLUS Continuous Glucose Monitor featured more excellent accuracy especially during changes of glucose rates and in the “hypo-zone”. It produces trend graphs at the first hour, third hour, sixth hour, twelfth hour, and twenty-fourth hour. Trend arrows will tell the patient where the glucose is heading. When the glucose level goes over or below a user-defined level, the Monitor will provide alerts to the patient. It has water-resistant sensor. The device is rechargeable. The Monitor can hold up to thirty days of patient data.